Debiopharm’s Debio 1143 Receives the US FDA’s Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer

 Debiopharm’s Debio 1143 Receives the US FDA’s Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer

Debiopharm’s Debio 1143 Receives the US FDA’s Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer

Shots:

  • The BTD is based on P-II results that demonstrated improvement of the 1EPs locoregional control rate @18mos. after CRT (21% improvement vs. control arm) and a marked PFS benefit vs the CRT + PBO arm after a 2-year follow-up period
  • The BTD reaffirms that Debio 1143 has the potential to offer benefit over the current SOC in LA-SCCHN, responding to the high unmet need in this debilitating cancer type
  • Debio 1143 is a potential first-in-class oral antagonist of IAPs, sensitizes tumor cells to radio-CT by promoting programmed cell death and fostering anti-tumor immunity

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Debiopharm

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post